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Randomized clinical trials (RCTs) and real-world data (RWD) in patients with atrial fibrillation
have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral anticoagu-
lants (NOACs) are at least as effective in the prevention of ischaemic stroke, while decreas-
ing the risk of bleeding.
Objective
We aim to evaluate the cost-effectiveness of the NOAC apixaban versus other NOACs
(dabigatran, edoxaban and rivaroxaban) and VKA, for stroke prevention in patients with
atrial fibrillation by including the available data both from RCT and real-world analyses of all
NOACs into one integrative previously published model.
Methods
The model was updated to the current Dutch healthcare situation. The incremental cost-
effectiveness ratio was calculated using either efficacy/effectiveness and safety data
derived from a network meta-analysis (NMA) synthesizing NOAC RCTs or RWD. We con-
ducted a systematic literature search to identify eligible publication to best inform the RWD-
based analysis. Additional sensitivity and scenario analyses were conducted to test the
robustness of the outcomes.
Results
In the NMA-based analysis, apixaban appeared to be cost-effective compared to VKA
(€3,506 per quality adjusted life-year) and dominant (cost-saving and more effective) over
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dabigatran 110 mg, dabigatran 150 mg, edoxaban and rivaroxaban. In the RWD-based
analysis, apixaban was dominant over all other anticoagulants. In the scenario analysis
apixaban appeared to be not cost-effective compared to dabigatran 150 mg, when using
equal event-unrelated treatment discontinuation rates for each drug. In all other scenarios
apixaban is cost-effective or cost-saving compared to VKA and other NOACs.
Conclusion
Based on RCTs as well as RWD, we conclude that apixaban is generally cost-effective or
even cost-saving (less costly and more effective) compared to VKA and other NOACs in the
overall population of patients with atrial fibrillation.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a major cause of ische-
mic stroke, heart failure and cardiovascular morbidity [1]. In the Netherlands, the prevalence
in the total population is 2–3% [2] and in people of 75 years and older the prevalence of AF
increases to more than 10% [3]. Furthermore, also due to the aging population, the number of
patients with AF is predicted to rise steeply in the coming years [1].
AF constitutes a significant public health problem, and estimates suggest that this condition
accounts for 1.3% of the national healthcare budget in the Netherlands with a total estimated
cost of €583 million in 2009 [4]. In patients with AF, the associated increased risks of ischae-
mic stroke and systemic embolism (SE) present a major challenge. Approximately 20–30% of
the patients experiencing ischaemic stroke have been diagnosed with AF before, during or
after the stroke event [1]. Embolic events, such as ischaemic stroke, lead to high hospitalization
costs and long-term maintenance costs which contributes to the high economic burden to the
Dutch health care system [5].
In patients with AF, anticoagulant (AC) therapy with vitamin K antagonists (VKAs) has
been the most effective treatment for the prevention of stroke over the last decades. However,
on the basis of randomized clinical trial (RCT) results, the European guidelines have adopted
the non-vitamin K antagonist oral anticoagulants (NOACs) as the preferred treatment for the
prevention of stroke in patients with AF since 2012 [1,6]. A network meta-analysis (NMA) on
pivotal RCTs in treatment groups with NOACs versus the VKA warfarin included data on
almost 72,000 patients [7], showed that NOACs were at least as effective in the prevention of
ischaemic stroke compared to VKA while there was a 50% decrease in the incidence of hae-
morrhagic stroke. Over the last years, real-world data (RWD) on the effectiveness and safety of
NOACs have been published, confirming the results of the RCTs.
In terms of effectiveness, safety and costs it is relevant to investigate whether the results of
the cost-effectiveness using RWD support results of analyses based on RCTs (external valida-
tion). Multiple cost-effectiveness analyses have been published on the different NOACs versus
VKAs on the basis of the respective RCTs results, using different models and cost assumptions.
Here, we aim to evaluate the cost-effectiveness of the NOAC apixaban versus other NOACs
and VKAs for stroke prevention in patients with AF by including the available data both from
NMA and real-world analyses of all available NOACs in one integrative previously published
model [8].
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Methods
We aim to evaluate the cost-effectiveness of apixaban compared to VKA, dabigatran, rivaroxa-
ban and edoxaban, by capturing all costs and health outcomes related to the disease, treatment
and complications, during the lifetime of a patient with AF. The primary outcome of our anal-
ysis is the incremental cost-effectiveness ratio (ICER), calculated by dividing the incremental
costs by the incremental health outcomes, presented in life-years LY and quality adjusted life-
years (QALY). The ICER is compared to a willingness-to-pay (WTP) threshold of €20,000/
QALY. This threshold is based on the disease burden calculation (proportional shortfall esti-
mate of 0.14) in the calculation tool as recommended by the Dutch guidelines for pharmacoe-
conomic research [9]. The ICER will be calculated using either efficacy/effectiveness and safety
data derived from an NMA synthesizing RCTs on NOACs [10] (NMA-based analysis) or
RWD (RWD-based analysis).
We conducted a systematic literature search to identify eligible publication to best inform
the RWD-based analysis. The systematic literature search was conducted with help of the ‘Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement’,
to identify RWD studies eligible for the RWD-based analysis [11]. Details on the method as
well as the results of the search strategy are described in S1. Following the pre-defined eligibil-
ity criteria, the real-world study of Lip et al. [12] was considered the most appropriate for use
in the RWD-based analysis. From this real-world study we obtained patient characteristics and
real-world event rates to populate the RWD-based model. The model structure and all other
input parameters were equal for both analyses.
Model structure
Both the NMA-based and the RWD-based analyses were based on a previously published Mar-
kov model [8]. The model was validated and updated with data based on the most recent litera-
ture to evaluate the lifetime costs and health effects of treatment with apixaban compared to
VKA and other NOACs in AF patients in the Netherlands. Since this model was designed with
apixaban as the reference drug, indirect comparison between other NOACs (dabigatran, edox-
aban and rivaroxaban) and comparison of other NOACs to VKA, was not possible [8]. To
model the disease course of AF, different health states were included in the model. During a
lifetime, a hypothetical cohort of 1,000 AF patients could remain in or move through these dif-
ferent health states. The risk to move to another health state, hereafter mentioned as the transi-
tion probability, was calculated per six weeks cycle. This cycle length was chosen to capture all
events related to AF within such a short time frame [8]. As shown in Fig 1, the model included
the following health states: ‘AF’, ‘ischaemic stroke’ (including unspecified strokes), ‘SE’, ‘bleed-
ing’, myocardial infarction (‘MI’), ‘other deaths’ (all deaths unrelated to the aforementioned
events) and ‘event unrelated AC discontinuation’ (AC discontinuation unrelated to the events
explicitly included). Bleeding events were divided into intracranial haemorrhage (referred to
as ‘ICH’, which was assumed to be the composite of ‘haemorrhagic stroke’ and ‘other ICH’),
other major bleeding (referred to as ‘other MB’, defined as all non-ICH MBs) and clinically rel-
evant non-major bleeding (‘CRNMB’). Additionally, a distinction was made between different
levels of ischaemic and haemorrhagic stroke severity (i.e. mild, moderate and severe).
All patients entered the model in the ‘AF’ state. Upon the occurrence of a clinical event the
patient remained in the corresponding health state for one cycle and then moved to one of the
transient or absorbing states. ‘AF’ and ‘AF without AC therapy’ (red squares) reflect transient
states, meaning that patients were able to remain in them or move to other states in the model.
In absorbing states (e.g. ‘death’ [blue squares]) patients remained until death. Upon the
Real-world and trial based cost-effectiveness of oral anticoagulants in atrial fibrillation
PLOS ONE | https://doi.org/10.1371/journal.pone.0222658 September 17, 2019 3 / 17
occurrence of ‘event unrelated AC discontinuation’ patients were assumed to discontinue AC
therapy permanently.
Patient characteristics
In the NMA-based and RWD-based analyses, all patients entered the model with baseline
characteristics as presented in S1 Table. In the NMA-based analysis, we used a Dutch study
[13] to simulate specific Dutch patient characteristics, adapting the NMA to the specific Dutch
context. The patients entered the model aged 72, 64.7% were male and the average CHADS2
score and CHA2DS2-VASc score were 1.7 and 3.1, respectively. In the RWD-based analysis,
the patient characteristics were based on the selected real-world study itself. The patients were
on average 74.3 years old, 54.1% were male and the average CHA2DS2-VASc score was 3.7.
Transition probabilities
Event rates. In the NMA-based analysis, transition probabilities were based on the clinical
event risks in patients receiving apixaban and a VKA (warfarin) in the ARISTOTLE trial [14].
Fig 1. Representation of the Markov model. All patients entered the model in the AF state, from where they could move to
another health state upon the occurrence of one of the following events: ‘ischaemic stroke’, ‘haemorrhagic stroke’, ‘other ICH’,
‘other MB’, ‘CRNMB’, ‘SE’, ‘MI’, ‘other deaths’ or ‘event unrelated AC discontinuation’. The triangles show the state a patient
enters after an event. These states can be transient (red squares) or absorbing (blue squares). Abbreviations: AC, anticoagulant;
AF, atrial fibrillation; CRNMB, clinically relevant non-major bleeding; ICH, intracranial haemorrhage; MB, major bleeding; MI,
myocardial infarction; SE, systemic embolism.
https://doi.org/10.1371/journal.pone.0222658.g001
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Hazard ratios compared to apixaban for the comparators dabigatran (110 mg and 150 mg), riv-
aroxaban and edoxaban were obtained from an NMA by Lip et al [10], who made pairwise
indirect comparisons between the ARISTOTLE [14], RE-LY [15], ROCKET-AF [16] and
ENGAGE-AF [17] trials, using propensity score adjustments. S2 Table shows the event rates
per 100 patient-years (PY) for apixaban and VKA and hazard ratios for dabigatran 110 mg,
dabigatran 150 mg, rivaroxaban and edoxaban. Lip et al. also included edoxaban 30 mg in his
analysis, however this low-dose was not approved by the European Medicines Agency and
therefore not included in our analysis. Average stroke and bleeding (ICH and other MB) risks
were weighted by multiplying the CHADS2 score distribution in Dutch patients (S1 Table)
with the corresponding event risks (S2 Table). Subsequently, the event rates were calculated
per six weeks (42 days) cycle [18]. Event rates for the other NOACs (dabigatran 110 mg, dabi-
gatran 150 mg, rivaroxaban and edoxaban) were based on the event rate of apixaban per cycle
multiplied by the hazard ratios (S2 Appendix) [18]. ‘Ischaemic stroke’ and ‘haemorrhagic
stroke’ health states were specified per severity, by the modified Rankin Scale (mRS), specify-
ing mild (mRS 0–2), moderate (mRS 3–4), severe (mRS 5) and fatal, based on RCT data [14–
17]. The model allowed for one recurring ischaemic or haemorrhagic stroke, with an event
rate of 2.72 per 100 PY, which was assumed to be equal across all treatments [19].
The transition probabilities used in the RWD-based analysis are summarized in S3 Table.
Based on the real-world study by Lip et al. [12] we included RWD-based event rates of apixa-
ban and VKA and hazard ratios of dabigatran and rivaroxaban for ischaemic stroke, ICH,
other MB and SE, and distributions of haemorrhagic stroke among ICH and GI bleeding
among other MB. If transition probabilities were unavailable from RWD, we used the same
transition probabilities as used in the NMA-based analysis.
In sensitivity analysis, transition probabilities, hazard ratios and distributions were varied
with a beta, log normal and Dirichlet distributions, respectively.
Mortality. Mortality rates are summarized in S4 Table. Background mortality was calcu-
lated by fitting the Gompertz distribution to 2017 Dutch life tables to obtain a proper represen-
tation of the mortality risk for each six weeks cycle [20]. For each health state, background
mortality risks were updated by case fatality and mortality risk adjustment factors by using
data from the ARISTOTLE trial [14] within the trial period and data from a Danish study by
Brønnum et al. [21] for long term outcomes.
Treatment switch or discontinuation. Treatment discontinuation could be related or
unrelated to an event. Upon the occurrence of non-fatal other ICH, patients were assumed to
discontinue AC therapy for six weeks after which they resumed their original AC [22]. Patients
who experienced a non-fatal haemorrhagic stroke or non-fatal MI were assumed to discon-
tinue their AC therapy permanently and were assigned acute and long-term maintenance
costs. All patients experiencing any other event such as ischaemic stroke or SE were assumed
to continue their current AC therapy.
In case of ‘event unrelated AC discontinuation’, all event risks (e.g. event risk, case fatality,
severity distributions) were updated to no treatment. These event rates for patients receiving
no treatment, summarized in S5 Table, were obtained from a meta-analysis of placebo, aspirin
and warfarin controlled studies in AF [23]. After AC discontinuation we assumed no further
bleeding risk, and a constant risk of ischaemic stroke, SE, MI, and other CV hospitalisation,
independent of time, prior AC therapy or patient characteristics.
Utilities
In absence of health-state-specific EQ-5D Dutch utilities, health-state-specific utility scores
were obtained from a UK EQ-5D catalogue by Sullivan et al. [24] (Table 1), similar to the
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previously published UK model [8]. A specific score for AF patients was used and updated
upon the occurrence of a clinical event. Stroke (ischaemic and haemorrhagic) utility scores
were subdivided per severity. Utility decrements for other ICH, other MBs, CRNMB, other
CV hospitalization and use of AC therapy were taken into account [25,26]. Health outcomes
were discounted at a rate of 1.5% per year [27]. Utility (decrement) parameters were varied
using beta distributions for sensitivity analyses.
Costs
Direct and indirect costs in- and outside the healthcare sector were considered, since the
ICERs were calculated from a societal perspective, as recommended by the Dutch cost manual
for pharmacoeconomic evaluation [27]. All costs with their corresponding ranges are summa-
rized in Table 2. Ranges were based on a 95% confidence interval (CI). If 95% CI was unavail-
able, ranges were calculated with a standard error of 25% of the mean. Although this approach
has limitations, as discussed in ISPOR-SMDM modelling good research practices report [28],
the exclusion of parameters from a sensitivity analysis based on the fact that there is no data
available to estimate probabilistic parameters would be less appropriate. Drug costs were
derived from the offxicial Dutch price list (Z-index) from July 2018 [29]. The drug cost of
VKA was based on the weighted average cost of phenprocoumon (21,1%) and acenocoumarol
(78,9%) as reported in the annual medical report of the Dutch Federation of Thrombosis Ser-
vice (FNT) [2]. For VKA patients the cost of an INR monitoring visit was calculated as the
average cost of INR measurement at thrombotic service (45.6%), at home (34.0%) and self-
Table 1. Utilities for different health states.
Utility Value
Value, mean (standard error) Source
AF 0.7270 (0.1818) [24]
Ischaemic stroke
Mild 0.6151 (0.1538) [24]
Moderate 0.5646 (0.1412) [24]
Severe 0.5142 (0.1285) [24]
Haemorrhagic stroke
Mild 0.6151 (0.1538) [24]
Moderate 0.5646 (0.1412) [24]
Severe 0.5142 (0.1285) [24]
MI 0.6098 (0.1525) [24]
SE 0.6265 (0.1566) [24]
Utility Decrement
Value, mean (standard error or 95% CI) Duration Source
Other ICH (6 weeks) 0.1385 (0.0346) 6 weeks [25]
Other MB (2 weeks) 0.1385 (0.0346) 14 days [25]
CRNMB (2 days) 0.0600 (0.0150) 2 days [25]
Other CV hospitalization (6 days) 0.1276 (0.0319) 6 days [24]
Treatment with VKA 0.0130 (0.00–0.08) While receiving treatment [26]
Treatment with apixaban, dabigatran, rivaroxaban or edoxaban a 0.0020 (0.00–0.04) While receiving treatment [26]
a Utility decrement related to anticoagulation with NOACs is assumed to be equal to aspirin.
Abbreviations: AF, atrial fibrillation; CI, confidence interval; CRNMB, clinically relevant non-major bleeding; CV, cardiovascular; ICH, intracranial haemorrhage; MB,
major bleeding; MI, myocardial infarction; SE, systemic embolism, VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pone.0222658.t001
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measurement (20.4%) [27,30]. Based on the FNT medical report an average frequency of INR
monitoring visits was set at 22.3 per year. Routine care for NOACs consisted of an annual gen-
eral practitioner (GP) visit, since the European Society for Cardiology guidelines mention that
chronic care management can be handled by GP [1]. AC management consisted of an addi-
tional GP visit for AC related dyspepsia and renal function monitoring, which should for
NOACs be done at least once per year according to international guidelines [31].
Event costs per health state were divided into acute and long-term maintenance costs.
Acute costs were related to hospital and rehabilitation facility costs and maintenance costs
reflected medical costs during the patient’s lifetime [18]. Event costs were derived from our
previous Dutch economic study [5]. Costs for other CV hospitalizations were based on Dutch
hospital tariffs for hospitalization related to heart failure, high blood pressure and heart infec-
tions [32].
Indirect costs included travel expenses and event related informal care costs. Travel costs
were included for 45% of the INR monitoring visits (patients who visited thrombosis service
themselves) and for each routine care or dyspepsia related GP visits [33]. These costs were
based on an average distance to the GP of 1.1 km, with a cost of €0.19 per km [27]. Informal
care costs were added to other long-term maintenance costs following events with absorbing
states. Informal care costs for stroke (ischaemic and haemorrhagic) were based on the Dutch
costing study by van den Berg et al. (based on a mean of 29.4 hours of informal care per week)
[34]. MI and SE were assumed to require less intensive informal care compared to stroke, and
were therefore based on a Dutch report that defined non-intensive informal care as eight
hours per week. The price per hour (€14) was derived from the Dutch cost manual for phar-
macoeconomic evaluation [27].
All costs were inflated to 2018 using the consumer price index from Dutch Statistics (CBS
Statline) [35]. Cost outcomes were discounted at a rate of 4% per year [27]. For sensitivity anal-
yses the costs parameters were varied over a gamma distribution.
Sensitivity and scenario analyses
Next to base case analyses based on the NMA and RWD, sensitivity analyses were conducted
to evaluate the influence of uncertainty in input parameters on the ICER. In the probabilistic
sensitivity analysis (PSA) costs, utilities, transition probabilities were varied simultaneously
over their 95% CIs and ICERs were calculated during 2,000 simulations. Outcomes were pre-
sented in cost-effectiveness planes and cost-effectiveness acceptability curves. In the univariate
sensitivity analysis input parameters were varied one by one over their 95% CI, to examine the
influence on the ICER for each parameter separately. The input parameters with the highest
impact on the ICER were presented in a Tornado diagram. Three additional scenario analyses
were conducted to capture the effect of healthcare payer’s perspective (scenario 1), equal drug




Table 3 summarizes the costs outcomes per category. Event costs are the largest contributor to
the total costs (45–49% and 47–53% in the NMA-based and RWD-based analyses, respec-
tively). Indirect costs also have high impact on the total costs: in both analyses 39–45% of the
total costs are related to indirect costs. In VKA treated patients, the impact of drug costs is neg-
ligible compared to NOACs (<1%% vs. 8–10% of total costs). Overall relatively small
Real-world and trial based cost-effectiveness of oral anticoagulants in atrial fibrillation
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Table 2. Drug costs, event costs and indirect costs for the different health states.
Drug costs
Drug Average daily cost Source
Apixaban (5 mg BID) €2.18 [29]
VKA (3 mg daily) €0.05 a [29]
Dabigatran (110 mg BID) €2.44 [29]
Dabigatran (150 mg BID) €2.44 [29]
Rivaroxaban (20 mg daily) €2.29 [29]
Edoxaban (60 mg daily) €2.39 [29]
Monitoring and routine care costs
Unit Cost per unit (range) Source
INR monitoring visit (VKA) €15.03 €8.59 - €23.24) b [30]
Routine care related to AF (NOAC) €33.76 (€19.30 - €52.21) c [27]
AC management
Dyspepsia related GP visit €33.76 (€19.30 - €52.21) c [27]
Renal monitoring €6.69 (€3.82 - €10.35) [27]
Event costs
Event Acute care cost (range) Long-term maintenance cost per month (range) Source
Ischaemic or haemorrhagic stroke
Mild €15,623 (€11,367 - €21,473) €202 (€147- €278) [25]
Moderate €38,595 (€28,081 - €53,046) €1,507 (€1,096 - €2,071) [25]
Severe €46,877 (€34,107 - €64,428) €3,087 (€1,401 - €2,646) [25]
Fatal €3,088 (€1,765 - €4,774) [25]
Other ICH €21,004 (€15,283 - €28,869) [25]
Other MB €5,162 (€3,756 - €7,095) [25]
CRNMB €31.73 (€23 - €43) [25]
MI €5,189 (€5,101 - €5,276) €202.54 (€189 - €213) [25]
SE €5,538 (€3,165 - €8,563) €202.54 (€189 - €213) [25]
Other CV hospitalization €1,657 (€947 - €2,562) d [32]
Indirect costs
Unit Acute care cost (range) Long-term maintenance cost per month (range) Source
Travel costs
INR monitoring visit (VKA) €0.08 (€0.05 - €0.13) [27]
Routine care related to AF (NOAC) €0.21 (€0.12 - €0.32) [27]
AC management €0.21 (€0.12 - €0.32) [27]
Informal care costs
Ischaemic or haemorrhagic stroke
Mild €1,065 (€609 - €1,646) [34]
Moderate €1,407 (€804 - €2,176) [34]
Severe €1,750 (€1,000 - €2,705) [34]
MI €497 (€284 - €768) [27,30]
SE €497 (€284 - €768) [27,30]
a Based on weighted average of phenprocoumon and acenocoumarol users in the Netherlands
b Assumption: weighted average of costs based on declaration codes for measurement at thrombotic service (DOT: 079995), at home (DOT: 079995 and 079986) and
self-measurement/management (DOT: 190253)
c Based on cost of one GP visit
d Average of Dutch declaration codes for hospitalization of maximal 5 days for heart failure (DOT: 099899089), infection in the heart (DOT: 099899013) and high blood
pressure (DOT: 090301003).
Abbreviations: AC, anticoagulant; AF, atrial fibrillation; BID, twice daily; CRNMB, clinically relevant non-major bleeding; CV, cardiovascular; GI, gastro-intestinal; GP,
general practitioner; ICH, intracranial haemorrhage; INR, international normalized ratio; MB, major bleed; MI, myocardial infarct; NOAC, non-vitamin K antagonist
oral anticoagulant; SE, systemic embolism; VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pone.0222658.t002
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differences in total costs were observed across different types of NOACs. The total costs of AF
with NOACs as well as VKA treatment are lower in real-world setting compared to the trial
setting.
The deterministic results of the NMA-based and RWD-based analyses are summarized in
Table 4. In NMA-based analysis, apixaban increases costs with €902 and QALYs with 0.262
over lifetime compared to VKA, resulting in an ICER of €3,506/QALY. In both analyses, all
other ICERs were dominant, meaning that apixaban treatment is cost-saving while increasing
patient’s health.
Sensitivity analyses
The results of the PSA are plotted in cost-effectiveness planes, shown in S1 File. Figs 2 and 3
show the probability of being the most cost-effective treatment alternative per WTP thresh-
old for the NMA-based and RWD-based analyses, respectively. In NMA-based analysis,
apixaban is the most cost-effective treatment option at the €20,000/QALY WTP threshold
with 50%. At the same threshold, the probabilities of VKA, dabigatran 110 mg, dabigatran
150 mg, rivaroxaban and edoxaban being the most cost-effective treatment option are: 8%,
1%, 11%, 9% and 21%, respectively. In RWD-based analysis, similar results were found:
apixaban is the most cost-effective treatment with 90%, and apixaban was–compared to
VKA, dabigatran and rivaroxaban respectively—cost-effective in 0%, 0% and 9% of the iter-
ations. Nevertheless, apixaban was only significantly dominant compared to VKA in the
RWD-based analysis, as in more than 95% of the PSA simulations apixaban was cost-saving
and more effective compared to VKA. In all other PSAs the dominancy of apixaban was
non-significant.
Additionally, we conducted a univariate sensitivity analysis. Fig 4 represents the tornado
diagram for apixaban versus VKA (NMA-based analysis). Univariate sensitivity analyses com-
paring apixaban with other NOACs identified similar parameters to be the most influential on
ICER. The parameters with the most influence are the ischaemic stroke and ICH hazard ratios
for VKA compared to apixaban, INR monitoring costs, daily costs of apixaban and stroke
(ischaemic or haemorrhagic) case fatalities.
Table 3. Base-case costs outcomes of the NMA-based and RWD-based analyses presented as costs per patient over a lifetime horizon.
NMA-based analysis
Apixaban VKA Dabigatran 110 mg Dabigatran 150 mg Rivaroxaban Edoxaban
Drug costs € 3,925 (10%) € 95 (<1%) € 3,426 (8%) € 3,323 (8%) € 3,683 (9%) € 4,020 (10%)
Monitoring/ management costs € 1,181 (3%) € 2,192 (5%) € 1,148 (3%) € 1,179 (3%) € 1,174 (3%) € 1,176 (3%)
Event costs € 18,573 (45%) € 19,872 (49%) € 20,227 (46%) € 19,320 (46%) € 19,100 (46%) € 18,470 (45%)
Indirect costs € 17,289 (42%) € 18,005 (45%) € 18,811 (43%) € 17,905 (43%) € 18,010 (43%) € 17,463 (42%)
Total costs € 40,968 € 40,163 € 43,612 € 41,726 € 41,967 € 41,129
RWD-based analysis
Apixaban VKA Dabigatran Rivaroxaban
Drug costs € 3,747 (10%) € 91 (<1%) € 3,232 (8%) € 3,532 (9%)
Monitoring/ management costs € 1,059 (3%) € 2,017 (5%) € 1,034 (3%) € 1,048 (3%)
Event costs € 16,922 (47%) € 19,522 (53%) € 18,793 (48%) € 17,865 (48%)
Indirect costs € 13,974 (39%) € 15,535 (42%) € 16,224 (41%) € 14,869 (40%)
Total costs € 35,703 € 37,165 € 39,284 € 37,314
Abbreviations: NMA, network meta-analysis; RWD, real-world data; VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pone.0222658.t003
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Scenario analyses
We conducted three additional scenarios to assess the influence of the healthcare payer’s per-
spective (scenario 1), equal drug costs among NOACs (scenario 2) and equal rates of event
unrelated AC discontinuation among NOACs and VKAs (scenario 3). Scenario 1 showed that
compared to societal perspective the incremental costs of apixaban versus VKA and edoxaban
in the NMA-based analysis increase, resulting in an ICER of €5,787/QALY and €206/QALY.
In RWD-based analysis, apixaban is cost-effective compared to VKA (€292/QALY), and
cost-saving (dominant) compared to dabigatran and rivaroxaban. In scenario 2, equal drug
costs for NOACs resulted in an ICER of €2,884/QALY for apixaban versus edoxaban in the
NMA-based analysis. All other ICERs are dominant.
In the third scenario of the NMA-based analysis, equal event unrelated AC discontinuation
rates for NOACs and VKAs resulted in an ICER of €244,079/QALY for apixaban versus dabi-
gatran 150 mg, which is not considered cost-effective at the WTP threshold of €20,000/QALY.
In NMA-based analysis, apixaban appeared to be dominant over dabigatran 110 mg and rivar-
oxaban and cost-effective compared to VKA (€5,648/QALY) and edoxaban (€10,243/QALY).
Table 4. Base-case results of the NMA-based and RWD-based analyses comparing apixaban to VKA and other NOACs.
Comparator Incremental cost Incremental QALY Cost per QALY gained Incremental LY Cost per LY gained
NMA-based analysis
VKA €920 0.262 €3,506 0.269 €3,415
Dabigatran (110mg) - €2,692 0.177 Dominant 0.207 Dominant
Dabigatran (150 mg) - €819 0.131 Dominant 0.157 Dominant
Rivaroxaban - €1,027 0.101 Dominant 0.126 Dominant
Edoxaban - €197 0.065 Dominant 0.085 Dominant
RWD-based analysis
VKA - €1,358 0.330 Dominant 0.352 Dominant
Dabigatran - €3,612 0.310 Dominant 0.383 Dominant
Rivaroxaban - €1,625 0.124 Dominant 0.154 Dominant
Abbreviations: LY, life-years; NMA, network meta-analysis; QALY, quality adjusted life-years, RWD, real-world data; VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pone.0222658.t004
Fig 2. Probability of being the most cost-effective treatment choice per willingness-to-pay threshold for the NMA-
based analysis. Abbreviations: NMA, network meta-analysis; QALY, quality adjusted life-years; VKA, vitamin K
antagonist.
https://doi.org/10.1371/journal.pone.0222658.g002
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In RWD-based analysis apixaban was still dominant over VKA, dabigatran and rivaroxaban.
Detailed results of the three scenarios are presented in Table 5.
Discussion
To our knowledge, this is the first cost-effectiveness study comparing different NOACs and
VKA with RCT data as well as RWD in patients with AF. The RWD-based analysis was specifi-
cally implemented to externally validate conclusions found in the NMA-based analysis based
on RCT data. In the NMA-based analysis, apixaban appeared to be cost-effective compared to
VKA and cost-saving compared to dabigatran 110 mg, dabigatran 150 mg, rivaroxaban and
edoxaban. The RWD-based analysis showed that apixaban is cost-saving compared to all com-
parators. Apixaban was shown, in both analyses, to be the most cost-effective treatment option
at a WTP threshold of €20,000/QALY (50% and 90%, respectively). In the scenario analysis
apixaban appeared to be not cost-effective compared to dabigatran 150 mg, when using equal
event-unrelated treatment discontinuation rates for each drug. In all other scenarios apixaban
is cost-effective or cost-saving compared to VKA and other NOACs.
Fig 3. Probability of being the most cost-effective treatment choice per willingness-to-pay threshold for the
RWD-based analysis. Abbreviations: QALY, quality adjusted life-years; RWD, real-world data; VKA, vitamin K
antagonist.
https://doi.org/10.1371/journal.pone.0222658.g003
Fig 4. Univariate sensitivity analysis of NMA-based analysis comparing apixaban and VKA. Figure depicts the
influence of uncertainty in different input parameters on ICER. Abbreviations: AF, atrial fibrillation; HR, hazard
ratio, ICER, incremental cost-effectiveness ratio; ICH, intracranial haemorrhage; INR, international normalized ratio;
QALY, quality adjusted life-years; SE, systemic embolism; VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pone.0222658.g004
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A previously published cost-effectiveness analysis, which was based on the same model as
our analysis, was conducted in the UK setting [8]. They found that apixaban was cost-effective
compared to dabigatran 110 mg, dabigatran 150 mg and rivaroxaban with ICERs of £4,497/
QALY, £9,611/QALY and £5,305/QALY, respectively. In our analysis, we found apixaban to
be dominant (cost-saving while increasing QALYs) over the other NOACs. This difference
can be explained by the drug costs (apixaban is relatively lower priced in the Netherlands) as
well as the difference in perspective, with UK consistently using the health-care perspective,
i.e. that of the National Health Service (NHS). In our scenario analysis conducted from a
healthcare payer’s perspective, the incremental costs did decrease compared to the societal per-
spective, supporting this hypothesis, although the ICERs remained dominant. Moreover, in
Table 5. Results of the scenario analyses: NMA-based and RWD-based analyses calculated from healthcare payer’s perspective (scenario 1), equal drugs costs for
NOACs (scenario 2) and equal event unrelated AC discontinuation rates for NOACs and VKAs (scenario 3).
Scenario 1: healthcare payer’s perspective
Comparator Incremental cost Incremental QALY Cost per QALY gained Incremental LY Cost per LY gained
NMA-based analysis
VKA €1,518 0.262 €5,787 0.269 €5,636
Dabigatran (110mg) - €1,122 0.177 Dominant 0.207 Dominant
Dabigatran (150 mg) - €142 0.131 Dominant 0.157 Dominant
Rivaroxaban - €277 0.101 Dominant 0.126 Dominant
Edoxaban €13 0.065 €206 0.085 €157
RWD-based analysis
VKA €96 0.330 €292 0.352 €273
Dabigatran - €1,331 0.310 Dominant 0.383 Dominant
Rivaroxaban - €717 0.124 Dominant 0.154 Dominant
Scenario 2: equal drug costs for NOACs
Comparator Incremental cost Incremental QALY Cost per QALY gained Incremental LY Cost per LY gained
NMA-based analysis
Dabigatran (110mg) - €2,287 0.177 Dominant 0.207 Dominant
Dabigatran (150 mg) - €411 0.131 Dominant 0.157 Dominant
Rivaroxaban - €828 0.101 Dominant 0.126 Dominant
Edoxaban €186 0.065 €2,884 0.085 €2,193
RWD-based analysis
Dabigatran - €3,244 0.330 Dominant 0.383 Dominant
Rivaroxaban - €1,448 0.124 Dominant 0.154 Dominant
Scenario 3: equal event unrelated AC discontinuation rate for NOACs and VKAs
Comparator Incremental cost Incremental QALY Cost per QALY gained Incremental LY Cost per LY gained
NMA-based analysis
VKA €1,390 0.246 €5,648 0.249 €5,580
Dabigatran (110mg) - €675 0.082 Dominant 0.103 Dominant
Dabigatran (150 mg) €1,959 0.008 €244,079 0.022 €90,398
Rivaroxaban - €100 0.056 Dominant 0.077 Dominant
Edoxaban €385 0.038 €10,243 0.055 €6,951
RWD-based analysis
VKA - €1,241 0.326 Dominant 0.348 Dominant
Dabigatran - €2,828 0.291 Dominant 0.373 Dominant
Rivaroxaban - €1,215 0.100 Dominant 0.129 Dominant
Abbreviations: AC, anticoagulant; LY, life-years; NMA, network meta-analysis; QALY, quality adjusted life-year; RWD, real-world data; VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pone.0222658.t005
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our scenario analysis assuming equal AC costs apixaban was still dominant over all other
NOACs except edoxaban in the NMA-based analysis, with an ICER of €2,884/QALY. This
suggests that these differences in methodology are not solely the cause of the difference in
ICERs.
In a follow-up publication [18], it was concluded that, apixaban was dominant over 30 mg
and 60 mg edoxaban in the UK setting (with edoxaban not being included in the previous pub-
lication [8]). Two other studies in the UK calculated the cost-effectiveness based on alternative
NMAs [36,37]. Both studies showed that, compared to the other NOACs, apixaban is the most
cost-effective treatment option at a WTP threshold of £20,000/QALY.
A Dutch study that compared the cost-effectiveness of apixaban, rivaroxaban and dabiga-
tran to VKA [38] found that from a healthcare payer’s perspective apixaban was the most cost-
effective option compared to VKA with an ICER of €14,626/QALY. The difference in outcome
compared to our study can be explained by differences in input parameters (e.g. apixaban drug
costs were higher compared to our analysis) and model structure. For example, they did not
include haemorrhagic stroke costs and QALYs, which in our univariate analysis had the high-
est influence on the ICER. Also, they used the healthcare payer’s perspective and US tariffs for
the quality of life, which might also contribute to different outcomes.
Event unrelated AC discontinuation rates differ among the anticoagulants [10]. To show
the impact of these differences in event unrelated AC discontinuation rates on cost-effective-
ness, we included a scenario assuming equal rates for all anticoagulants. This scenario shows
to have a high influence on the ICER of apixaban compared to dabigatran 150 mg, which
changed from dominant to €244,079/QALY. Apixaban remained cost-effective or cost-saving
compared to the other NOACs and VKA. Firstly, dabigatran has the highest event unrelated
AC discontinuation rate compared to apixaban (hazard ratio versus apixaban = 1.500). Sec-
ondly, dabigatran 150 mg has a better protective effect (hazard ratio versus apixaban = 0.790)
compared to apixaban, while bleedings are a bit more frequent (hazard ratio versus apixaban
ICH = 1.020 and other MB = 1.340). When assuming equal event unrelated AC discontinua-
tion, the incremental QALYs of apixaban versus dabigatran 150 mg decreases from 0.131 in
the base-case analysis to 0.008, resulting in a high ICER.
Notably, costs and QALYs are highly driven by the patients who discontinue AC therapy.
Treatment discontinuation in patients with AF is very undesirable, because from that moment
on they are not protected for stroke or other thromboembolic events. In practice, a certain per-
centage of the patients who discontinue their initial AC therapy, will be encouraged to switch
to another AC. However, it is hard to get supportive data on the percentage of patients fully
discontinuing AC therapy, as well as reliable data on what that exactly means for stroke and
bleeding risks. By emphasizing the importance of AC therapy and discussing the reason for
the AC discontinuation the patient can be encouraged to restart or switch AC therapy.
The major advantage of this study is that both an NMA and RWD were used for cost-effec-
tiveness. For the RWD-based analysis we used the publication of Lip et al. that best met the
inclusion criteria for the systematic literature search underlying the NMA [12]. Differences in
estimated hazard ratios in NMA and RWD led to differences in results, although the overall
outcomes of the RWD-based analysis support the conclusions of the NMA-based analysis.
Unfortunately, we were unable to include RWD on Dutch patients. Throughout the next
years, a recently launched project “DUTCH-AF registry” aims to include 6,000 Dutch patients
with AF to collect and assess data on effectiveness, adherence and bleeding risk of NOACs and
VKAs [39]. It is interesting to have this data specific on the Dutch patients, since the patient
characteristics, such as CHADS2/CHA2DS2-VASc scores and age, can obviously differ among
populations. Obviously due to the fact that RWD studies include heterogeneous populations
from different countries, differences in clinical outcomes can be expected, which potentially
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also leads to differences in economic outcomes. Therefore, the use of another RWD study
might lead to different outcomes. Also, outcomes of NMAs can vary when making use of dif-
ferent combinations of clinical trials, differences in methodology and the differences in defini-
tions of the outcomes [40], again potentially leading to other results than those based on our
selected NMA and RWD.
Notably, we included low-dose dabigatran (110 mg) in our analysis. We included this dose
since it was officially approved by European Medicines Agency [41], although it was approved
with the condition that this low-dose should be reserved for patients older than 80 years and/
or with a decreased renal function (eGFR<50 ml/min). Since this was not the population that
was exclusively followed in the dabigatran (RE-LY) trial included in the NMA [15], the risks
used in the model might not adequately represent the real-world situation, and possibly this
leads to a undervaluation of the (cost-) effectiveness of dabigatran 110 mg.
Conclusion
Based on RCT-data as well as RWD, we conclude that generally apixaban is cost-effective or
even cost-saving (less costly and more effective) compared to VKA and other NOACs in the
overall population of AF-patients. It should be mentioned that, especially compared to other
NOACs, only marginal differences in costs and health effects were found and the use of other
effectiveness and safety data sources or assumptions, considerations of specific patient popula-
tions, costs might lead to different outcomes.
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